Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navafenterol (AZD8871) in moderate to severe COPD
NCT03645434Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of navafenterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Change From Baseline in Trough FEV1 at Day 15 and Change From Baseline in COPD Assessment Test (CAT). Started Oct 2018; status: completed.
02
Drugs
navafenterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03645434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645434.